We provide you with 20 years of free, institutional-grade data for BMEA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BMEA. Explore the full financial landscape of BMEA stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2024-03-28 | 1840439 | BMEA | 10-K | Url |
| 2023-10-30 | 1840439 | BMEA | 10-Q | Url |
| 2023-07-31 | 1840439 | BMEA | 10-Q | Url |
| 2023-05-02 | 1840439 | BMEA | 10-Q | Url |
| 2023-03-28 | 1840439 | BMEA | 10-K | Url |
| 2022-11-07 | 1840439 | BMEA | 10-Q | Url |
| 2022-08-01 | 1840439 | BMEA | 10-Q | Url |
| 2022-05-16 | 1840439 | BMEA | 10-Q | Url |
| 2022-02-28 | 1840439 | BMEA | 10-K | Url |
| 2021-11-03 | 1840439 | BMEA | 10-Q | Url |
| 2021-08-11 | 1840439 | BMEA | 10-Q | Url |
| 2021-05-27 | 1840439 | BMEA | 10-Q | Url |
| 2021-03-26 | 1840439 | BMEA | S-1 | Url |
Biomea Fusion, Inc.(NASDAQ:BMEA) 
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibit...
Website: http://www.biomeafusion.com
Founded: 2017
CEO: Thomas Butler
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about BMEA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.